S&P 500   4,219.73 (+0.95%)
DOW   33,115.80 (+0.63%)
QQQ   351.32 (+0.96%)
AAPL   179.91 (+1.50%)
MSFT   330.80 (+0.73%)
META   270.83 (+2.31%)
GOOGL   123.35 (+0.39%)
AMZN   122.69 (+1.75%)
TSLA   205.00 (+0.52%)
NVDA   394.40 (+4.24%)
NIO   7.49 (-0.53%)
BABA   82.91 (+4.22%)
AMD   119.75 (+1.30%)
T   15.81 (+0.51%)
F   12.05 (+0.42%)
MU   69.15 (+1.39%)
CGC   0.84 (+0.60%)
GE   104.50 (+2.93%)
DIS   88.67 (+0.81%)
AMC   4.60 (+2.22%)
PFE   38.01 (-0.03%)
PYPL   63.17 (+1.90%)
NFLX   403.15 (+2.00%)
S&P 500   4,219.73 (+0.95%)
DOW   33,115.80 (+0.63%)
QQQ   351.32 (+0.96%)
AAPL   179.91 (+1.50%)
MSFT   330.80 (+0.73%)
META   270.83 (+2.31%)
GOOGL   123.35 (+0.39%)
AMZN   122.69 (+1.75%)
TSLA   205.00 (+0.52%)
NVDA   394.40 (+4.24%)
NIO   7.49 (-0.53%)
BABA   82.91 (+4.22%)
AMD   119.75 (+1.30%)
T   15.81 (+0.51%)
F   12.05 (+0.42%)
MU   69.15 (+1.39%)
CGC   0.84 (+0.60%)
GE   104.50 (+2.93%)
DIS   88.67 (+0.81%)
AMC   4.60 (+2.22%)
PFE   38.01 (-0.03%)
PYPL   63.17 (+1.90%)
NFLX   403.15 (+2.00%)
S&P 500   4,219.73 (+0.95%)
DOW   33,115.80 (+0.63%)
QQQ   351.32 (+0.96%)
AAPL   179.91 (+1.50%)
MSFT   330.80 (+0.73%)
META   270.83 (+2.31%)
GOOGL   123.35 (+0.39%)
AMZN   122.69 (+1.75%)
TSLA   205.00 (+0.52%)
NVDA   394.40 (+4.24%)
NIO   7.49 (-0.53%)
BABA   82.91 (+4.22%)
AMD   119.75 (+1.30%)
T   15.81 (+0.51%)
F   12.05 (+0.42%)
MU   69.15 (+1.39%)
CGC   0.84 (+0.60%)
GE   104.50 (+2.93%)
DIS   88.67 (+0.81%)
AMC   4.60 (+2.22%)
PFE   38.01 (-0.03%)
PYPL   63.17 (+1.90%)
NFLX   403.15 (+2.00%)
S&P 500   4,219.73 (+0.95%)
DOW   33,115.80 (+0.63%)
QQQ   351.32 (+0.96%)
AAPL   179.91 (+1.50%)
MSFT   330.80 (+0.73%)
META   270.83 (+2.31%)
GOOGL   123.35 (+0.39%)
AMZN   122.69 (+1.75%)
TSLA   205.00 (+0.52%)
NVDA   394.40 (+4.24%)
NIO   7.49 (-0.53%)
BABA   82.91 (+4.22%)
AMD   119.75 (+1.30%)
T   15.81 (+0.51%)
F   12.05 (+0.42%)
MU   69.15 (+1.39%)
CGC   0.84 (+0.60%)
GE   104.50 (+2.93%)
DIS   88.67 (+0.81%)
AMC   4.60 (+2.22%)
PFE   38.01 (-0.03%)
PYPL   63.17 (+1.90%)
NFLX   403.15 (+2.00%)
NASDAQ:PULM

Pulmatrix (PULM) Stock Forecast, Price & News

$2.74
+0.01 (+0.37%)
(As of 11:36 AM ET)
Compare
Today's Range
$2.68
$2.74
50-Day Range
$2.63
$3.10
52-Week Range
$2.63
$7.50
Volume
3,030 shs
Average Volume
29,276 shs
Market Capitalization
$10.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Pulmatrix MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
266.3% Upside
$10.00 Price Target
Short Interest
Healthy
0.10% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($4.94) to ($5.11) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.79 out of 5 stars

Medical Sector

709th out of 1,006 stocks

Pharmaceutical Preparations Industry

360th out of 492 stocks


PULM stock logo

About Pulmatrix (NASDAQ:PULM) Stock

Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the development and discovery of novel inhaled therapeutics products. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov, and Robert S. Langer, Jr. on June 15, 2015 and is headquartered in Lexington, MA.

Receive PULM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pulmatrix and its competitors with MarketBeat's FREE daily newsletter.

PULM Stock News Headlines

The $193 Billion US-China War You Don't Know About
They're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.
H.C. Wainwright Remains a Buy on Pulmatrix (PULM)
Pulmatrix (NASDAQ:PULM) Posts Earnings Results
The $193 Billion US-China War You Don't Know About
They're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.
Pulmatrix Supports World Asthma Day 2023
See More Headlines

PULM Price History

PULM Company Calendar

Last Earnings
3/30/2023
Today
6/01/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PULM
Employees
24
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+266.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-18,840,000.00
Net Margins
-285.66%
Pretax Margin
-285.66%

Debt

Sales & Book Value

Annual Sales
$6.07 million
Book Value
$7.40 per share

Miscellaneous

Free Float
3,556,000
Market Cap
$9.96 million
Optionable
Optionable
Beta
0.76

Key Executives

  • Teofilo Raad
    President, Chief Executive Officer & Director
  • Peter B. Ludlum
    Chief Financial Officer
  • Aidan Curran
    Vice President-Research & Scientific Affairs
  • Margaret Wasilewski
    Chief Medical Officer
  • Michelle S. Siegert
    Secretary, Treasurer & Vice President-Finance













PULM Stock - Frequently Asked Questions

Should I buy or sell Pulmatrix stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pulmatrix in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PULM shares.
View PULM analyst ratings
or view top-rated stocks.

What is Pulmatrix's stock price forecast for 2023?

1 Wall Street research analysts have issued 12 month price objectives for Pulmatrix's stock. Their PULM share price forecasts range from $10.00 to $10.00. On average, they predict the company's share price to reach $10.00 in the next year. This suggests a possible upside of 266.3% from the stock's current price.
View analysts price targets for PULM
or view top-rated stocks among Wall Street analysts.

How have PULM shares performed in 2023?

Pulmatrix's stock was trading at $3.88 on January 1st, 2023. Since then, PULM shares have decreased by 29.6% and is now trading at $2.7297.
View the best growth stocks for 2023 here
.

Are investors shorting Pulmatrix?

Pulmatrix saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 3,700 shares, an increase of 184.6% from the April 30th total of 1,300 shares. Based on an average trading volume of 18,600 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.1% of the company's shares are sold short.
View Pulmatrix's Short Interest
.

When is Pulmatrix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our PULM earnings forecast
.

How were Pulmatrix's earnings last quarter?

Pulmatrix, Inc. (NASDAQ:PULM) posted its earnings results on Thursday, March, 30th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.44) by $0.30. The biotechnology company earned $1.71 million during the quarter, compared to analysts' expectations of $1.87 million. Pulmatrix had a negative net margin of 285.66% and a negative trailing twelve-month return on equity of 55.65%.

When did Pulmatrix's stock split?

Shares of Pulmatrix reverse split before market open on Tuesday, March 1st 2022. The 1-20 reverse split was announced on Tuesday, March 1st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Pulmatrix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pulmatrix investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Acasti Pharma (ACST), Biocept (BIOC), Heat Biologics (HTBX), Trevena (TRVN), TherapeuticsMD (TXMD), Verastem (VSTM) and Evoke Pharma (EVOK).

What is Pulmatrix's stock symbol?

Pulmatrix trades on the NASDAQ under the ticker symbol "PULM."

Who are Pulmatrix's major shareholders?

Pulmatrix's stock is owned by a variety of institutional and retail investors. Top institutional investors include Sabby Management LLC (6.02%) and Susquehanna International Group LLP (0.68%).
View institutional ownership trends
.

How do I buy shares of Pulmatrix?

Shares of PULM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pulmatrix's stock price today?

One share of PULM stock can currently be purchased for approximately $2.73.

How much money does Pulmatrix make?

Pulmatrix (NASDAQ:PULM) has a market capitalization of $9.96 million and generates $6.07 million in revenue each year. The biotechnology company earns $-18,840,000.00 in net income (profit) each year or ($5.17) on an earnings per share basis.

How can I contact Pulmatrix?

Pulmatrix's mailing address is 99 HAYDEN AVENUE SUITE 390, LEXINGTON MA, 02421. The official website for the company is www.pulmatrix.com. The biotechnology company can be reached via phone at (781) 357-2333, via email at rclarke@pulmatrix.com, or via fax at 707-525-9906.

This page (NASDAQ:PULM) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -